Antipsychotics and Weight Gain
Antipsychotic medicines, especially olanzapine and clozapine, commonly cause substantial weight gain and metabolic changes, so weight and blood tests must be monitored.
Plain English
Patient-Friendly Explanation
Antipsychotic medicines treat conditions such as schizophrenia and bipolar disorder, and some of them - particularly olanzapine and clozapine, and to a lesser degree risperidone and quetiapine - are among the most weight-promoting drugs in clinical use. Weight can rise by several kilograms within the first months of treatment and tends to plateau after about a year, and it comes with increases in blood sugar, blood fats and blood pressure that go beyond what the weight gain alone would explain. This weight gain is not a sign of weak willpower, and it is not a reason to stop treatment on your own, because stopping suddenly can cause the psychiatric illness to relapse. The right approach is monitoring plus active management: baseline and regular weight, waist, glucose and lipid checks, and a discussion with your psychiatrist about whether a less weight-promoting medicine or additional treatment is suitable.
Medical
Clinical Definition
Second-generation antipsychotics differ widely in metabolic liability, commonly ranked from highest to lowest as clozapine and olanzapine, then quetiapine, risperidone and paliperidone, then aripiprazole, amisulpride and ziprasidone, with the newer partial dopamine agonists comparatively weight-neutral. Mechanisms include histamine H1 and serotonin 5-HT2C receptor antagonism driving increased appetite and reduced satiety, modulation of hypothalamic energy regulation, and direct effects on insulin secretion and sensitivity; clinically significant weight gain often occurs within the first 6 to 12 weeks, with large individual variation influenced by age, baseline BMI, dose and genetic factors. Metabolic monitoring is therefore a standard of care: weight and BMI, waist circumference, fasting glucose or HbA1c, and a lipid profile at baseline, at 6 and 12 weeks, then at least annually, together with blood pressure and, where indicated, prolactin. Management options include switching to a metabolically favourable agent, adjunctive metformin, which has the strongest evidence among pharmacological countermeasures, behavioural and dietary intervention, and structured monitoring programmes; weight-loss pharmacotherapy and bariatric surgery may be considered in selected patients, weighing drug interactions and psychiatric stability. Such changes should always be made in consultation with the treating psychiatrist.
Key Insight
Why It Matters
Patients on antipsychotics often tell us nobody warned them about weight gain, and that they feel it is their fault. Monitoring weight, waist and metabolic bloods from the start - and treating the gain actively rather than accepting it - is part of good psychiatric care, not an optional extra.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
